Tetratherix Joint Venture Gets Ethics Approval for Clinical Trial of Hydrogel Spacer in Cancer Treatments

MT Newswires Live06-23

Tetratherix (ASX:TTX) said its Tutelix joint venture received ethics committee approval to launch a clinical trial for hydrogel spacer in Australia, according to a Tuesday filing with the Australian bourse.

The Tutelix hydrogel spacer is used during cancer treatments to protect healthy parts of the body from damage.

Positive six-month follow-up data confirms an opportunity for the product beyond the prostate cancer program, providing the company with a technical basis to pursue a gynaecological cancer indication, Tetratherix Chief Technology Officer Ali Fathi said.

The clinical study has completed enrolment of all 15 patients across multiple Australian sites, per the filing.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2645300206?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-23 11:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2645300206","market":"hk","top_or_hot":-1,"title":"Tetratherix Joint Venture Gets Ethics Approval for Clinical Trial of Hydrogel Spacer in Cancer Treatments","media":"MT Newswires Live","content":"<html><body><p> Tetratherix (ASX:TTX) said its Tutelix joint venture received ethics committee approval to launch a clinical trial for hydrogel spacer in Australia, according to a Tuesday filing with the Australian bourse.</p><p>The Tutelix hydrogel spacer is used during cancer treatments to protect healthy parts of the body from damage.</p><p>Positive six-month follow-up data confirms an opportunity for the product beyond the prostate cancer program, providing the company with a technical basis to pursue a gynaecological cancer indication, Tetratherix Chief Technology Officer Ali Fathi said.</p><p>The clinical study has completed enrolment of all 15 patients across multiple Australian sites, per the filing.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tetratherix Joint Venture Gets Ethics Approval for Clinical Trial of Hydrogel Spacer in Cancer Treatments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTetratherix Joint Venture Gets Ethics Approval for Clinical Trial of Hydrogel Spacer in Cancer Treatments\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-23 11:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Tetratherix (ASX:TTX) said its Tutelix joint venture received ethics committee approval to launch a clinical trial for hydrogel spacer in Australia, according to a Tuesday filing with the Australian bourse.</p><p>The Tutelix hydrogel spacer is used during cancer treatments to protect healthy parts of the body from damage.</p><p>Positive six-month follow-up data confirms an opportunity for the product beyond the prostate cancer program, providing the company with a technical basis to pursue a gynaecological cancer indication, Tetratherix Chief Technology Officer Ali Fathi said.</p><p>The clinical study has completed enrolment of all 15 patients across multiple Australian sites, per the filing.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IMLC.AU","symbol_name":"INV MUTUAL CONC AUS SHAR ETF","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2645300206","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2645300206","pubTimestamp":1782187060,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Tetratherix  said its Tutelix joint venture received ethics committee approval to launch a clinical trial for hydrogel spacer in Australia, according to a Tuesday filing with the Australian bourse.The Tutelix hydrogel spacer is used during cancer treatments to protect healthy parts of the body from damage.Positive six-month follow-up data confirms an opportunity for the product beyond the prostate cancer program, providing the company with a technical basis to pursue a gynaecological cancer indication, Tetratherix Chief Technology Officer Ali Fathi said.The clinical study has completed enrolment of all 15 patients across multiple Australian sites, per the filing.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IMLC.AU":"INV MUTUAL CONC AUS SHAR ETF","XJO.AU":"标普/澳交所 200指数","SLF.AU":"SPDR S&P/ASX 200 LISTED PROP","IIGF.AU":"Intelligent Investor Australian Equity Growth Fund (Managed Fund)","XKO.AU":"标普/澳交所 300指数","GEAR.AU":"BETASHARES GEARED AUS EQTY F","QFN.AU":"BetaShares Australian Fincls Sect ETF","QRE.AU":"BetaShares Australian Res Sect ETF","IISV.AU":"INTELL INV SELVAL SHR FD MF","ZYAU.AU":"Etfs S&p/asx 300 High Yield Plus Etf","JYNT":"The Joint Corp.","BBOZ.AU":"BETASHARES AUSTRALIAN STRONG BEAR (HEDGE FUND)","EIGA.AU":"EINVEST INCOME GENERATOR FD","VAP.AU":"VANGUARD AU PROP SEC IDX ETF","TTX.AU":"Tetratherix Ltd","DACE.AU":"DIMENSIONAL AUST CORE EQ","VAS.AU":"VANGUARD AUST SHARES IDX ETF","IOZ.AU":"iShares Core S&P/ASX 200","BEAR.AU":"BETASHARES AUS EQ BEAR HF","OZF.AU":"SPDR S&P/ASX 200 FINANCIALS","BK7067":"生物科技","STW.AU":"SPDR® S&P/ASX 200 ETF","BK4185":"保健护理机构","OZR.AU":"SPDR S&P/ASX 200 RESOURCES F","E200.AU":"SPDR S&P/ASX 200 ESG FUND","XAO.AU":"标普/澳交所 普通股指数","GIVE.AU":"PERPETUAL ESG AU SHR EQMF"},"translate_title":"Tetratherix合资企业获得水凝胶间隔物癌症治疗临床试验的伦理批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XJO.AU":0.63,"BEAR.AU":0.6,"STW.AU":0.6,"XAO.AU":0.63,"IIGF.AU":0.6,"XKO.AU":0.63,"TTX.AU":1,"ZYAU.AU":0.6,"VAP.AU":0.6,"OZR.AU":0.6,"OZF.AU":0.6,"SLF.AU":0.6,"E200.AU":0.6,"GIVE.AU":0.6,"IISV.AU":0.6,"JYNT":1.5,"VAS.AU":0.6,"IOZ.AU":0.6,"DACE.AU":0.6,"QRE.AU":0.6,"BBOZ.AU":0.6,"GEAR.AU":0.6,"QFN.AU":0.6,"IMLC.AU":0.6,"EIGA.AU":0.6},"content_text":"Tetratherix (ASX:TTX) said its Tutelix joint venture received ethics committee approval to launch a clinical trial for hydrogel spacer in Australia, according to a Tuesday filing with the Australian bourse.The Tutelix hydrogel spacer is used during cancer treatments to protect healthy parts of the body from damage.Positive six-month follow-up data confirms an opportunity for the product beyond the prostate cancer program, providing the company with a technical basis to pursue a gynaecological cancer indication, Tetratherix Chief Technology Officer Ali Fathi said.The clinical study has completed enrolment of all 15 patients across multiple Australian sites, per the filing.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2645300206","isCrawlerRequest":true}